The present disclosure relates to the compound having the following formula (I):which may be in base form or in the form of a hydrate or a solvate,in combination with prednisone or prednisolone,for its use for the treatment of castration resistant or hormone-refractory metastatic prostate cancer in patients not at risk of developing gastrointestinal disorders chosen from the group consisting of: gastrointestinal bleeding and perforation, gastritis, enterocolitis, neutropenic enterocolitis, colitis, intestinal obstruction, and ileus.
